Efficacy of additional hemoperfusion in hospitalized patients with severe to critical COVID-19 disease
3
Issued Date
2024-12-01
Resource Type
eISSN
20452322
Scopus ID
2-s2.0-85200223373
Journal Title
Scientific Reports
Volume
14
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Scientific Reports Vol.14 No.1 (2024)
Suggested Citation
Chiewroongroj S., Ratanarat R., Naorungroj T., Teeratakulpisarn N., Theeragul S. Efficacy of additional hemoperfusion in hospitalized patients with severe to critical COVID-19 disease. Scientific Reports Vol.14 No.1 (2024). doi:10.1038/s41598-024-68592-4 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/100393
Title
Efficacy of additional hemoperfusion in hospitalized patients with severe to critical COVID-19 disease
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
The evidence supporting additional hemoperfusion (HP) with cytokine adsorbents for improving clinical outcomes in severe to critical coronavirus disease 2019 (COVID-19) patients remains limited. We compared severe to critical COVID-19 patients who received additional HP with a cytokine adsorbent to matched cases receiving standard medical treatment (SMT). The primary outcome was hospital mortality. In our study, we matched 45 patients who received additional HP 1:1 with the SMT group based on key clinical parameters. The hospital mortality rates did not differ between the groups (33% vs 38%, p = 0.83). The HP group had a significantly shorter ICU stay (22 vs 32 days; p = 0.017) and reduced mechanical ventilation duration (15 vs 35 days; p < 0.001). Additionally, the incidence of pulmonary complications (20% vs 42%; p = 0.04), sepsis (38% vs 64%; p = 0.02), and disseminated intravascular coagulopathy (DIC) (13% vs 33%; p = 0.046) were significantly lower in the HP group. In conclusion, among severe to critical COVID-19 patients, additional HP with a cytokine adsorbent did not improve hospital mortality. However, it reduced ICU length of stay, mechanical ventilator days, and incidences of lung complications, sepsis, and DIC. Trial registration: TCTR20231002006. Registered 02 October 2023 (retrospectively registered).